Skip to main content
GutCited

사카로마이세스 보울라디 관련 여행자 설사

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

여행 5일 전부터 시작 시 RCT에서 여행자 설사가 25~40% 감소한 것으로 나타났습니다. 효과는 여행지에 따라 다릅니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

여행 5일 전부터 시작 시 RCT에서 여행자 설사가 25~40% 감소한 것으로 나타났습니다. 효과는 여행지에 따라 다릅니다.

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms 효과: None None

대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial n=47 8 weeks Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None vs: Placebo (Group I) and partial formulation (Group II) Outcome: IBS quality of life (QoL questionnaire) 효과: Dysphoria: median diff -5 (Group III) vs -1 (contr 0.0021 (dysphoria Group III)

대상 집단: Patients with IBS

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI 효과: None None

대상 집단: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs 효과: L. rhamnosus GG used by 91.8% None

대상 집단: Italian primary care pediatricians

Other n=70 16 weeks Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None vs: None (single-arm study) Outcome: Constipation scoring system change 효과: -5.3 (95% CI -5.9/-4.7) 0.001

대상 집단: Peritoneal dialysis patients with chronic constipation

Review
An update on probiotics in paediatrics.
Dose: None vs: None Outcome: GI disorder outcomes in paediatrics 효과: None None

대상 집단: Paediatric patients with GI disorders

Key Statistics

4

연구

3200

참여자

↑

Positive

B

등급

Referenced Papers

Current opinion in … 2025
Advances in experimental … 2024 2 인용
Advances in experimental … 2019 17 인용
The American journal … 2018 46 인용
Pediatric gastroenterology, hepatology … 2017 42 인용
Journal of pediatric … 2016 233 인용
Digestive diseases (Basel, … 2016 37 인용
The Cochrane database … 2015 233 인용
Journal of clinical … 2015 35 인용
Frontiers in immunology 2013 263 인용
Journal of clinical … 2011 432 인용
Journal for specialists … 2010 22 인용
American journal of … 2010
European journal of … 2009 91 인용
Current opinion in … 2009 82 인용
Advances in biochemical … 2008 535 인용
American family physician 2008
The Journal of … 2007 265 인용
The American journal … 2001 648 인용
International journal of … 2000 181 인용
Clinical infectious diseases … 1998 346 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

상한량: Well-tolerated up to 1,000 mg/day in clinical trials

연구에서 사용된 용량

용량 기간 효과 N
None -- Positive --
None 8 weeks Positive 47
None -- Positive --
None -- Mixed 279
None 16 weeks Positive 70
None -- Positive --
None -- Positive --
None -- Mixed --

권장 복용 시간: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

보고된 부작용

  • ⚠ Mild gas and bloating
  • ⚠ Rare: fungemia in critically ill patients with central venous catheters
  • ⚠ Thirst (yeast may increase water requirements)
  • ⚠ Very rare: potential environmental contamination risk in ICU settings

알려진 상호작용

  • ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

일일 최대 섭취 허용량: Well-tolerated up to 1,000 mg/day in clinical trials

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 사카로마이세스 보울라디 help with 여행자 설사?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that 사카로마이세스 보울라디 may support 여행자 설사 management. Our evidence grade is B (Good Evidence).
How much 사카로마이세스 보울라디 should I take for 여행자 설사?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 사카로마이세스 보울라디?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 사카로마이세스 보울라디 and 여행자 설사?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

관련 다른 성분: 여행자 설사

사카로마이세스 보울라디 다른 건강 상태에 대한 근거

References

  1. [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
  2. [2] Ailim Margarita Carías Domínguez et al.. Probiotics Antimicrob Proteins. 2025. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. doi:10.1007/s12602-024-10353-w PubMed
  3. [3] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
  4. [4] Qianfang Liu et al.. Front Cell Infect Microbiol. 2025. Saccharomyces boulardii and Bifidobacterium co-treatment for antibiotic associated diarrhea in pediatrics: a multicenter efficacy and safety study. doi:10.3389/fcimb.2025.1575605 PubMed
  5. [5] Adrianna Wierzbicka et al.. Front Nutr. 2025. Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and gut health markers in patients … doi:10.3389/fnut.2025.1603011 PubMed
  6. [6] Gennaro Argentino et al.. J Ren Nutr. 2025. Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study. doi:10.1053/j.jrn.2025.10.010 PubMed
  7. [7] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
  8. [8] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
  9. [9] Maria Zemła et al.. Curr Opin Clin Nutr Metab Care. 2025. An update on probiotics in paediatrics. doi:10.1097/MCO.0000000000001192 PubMed
  10. [10] Vladimir Hodzhev et al.. Open Forum Infect Dis. 2024. High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … doi:10.1093/ofid/ofae615 PubMed
  11. [11] Su-Wei Zhang et al.. Zhongguo Dang Dai Er Ke Za Zhi. 2024. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. doi:10.7499/j.issn.1008-8830.2401129 PubMed
  12. [12] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
  13. [13] Dhanasekhar Kesavelu et al.. Ther Adv Infect Dis. 2023. Current understanding of antibiotic-associated dysbiosis and approaches for its management. doi:10.1177/20499361231154443 PubMed
  14. [14] Qingrui Yang et al.. Front Pharmacol. 2023. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. doi:10.3389/fphar.2023.1153070 PubMed
  15. [15] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
  16. [16] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
  17. [17] Amarender S Puri. J Assoc Physicians India. 2023. The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. doi:10.5005/japi-11001-0235 PubMed
  18. [18] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  19. [19] Suparna Roy Sarkar et al.. Physiol Behav. 2021. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline. doi:10.1016/j.physbeh.2021.113411 PubMed
  20. [20] Dorota Czerucka et al.. World J Gastroenterol. 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. doi:10.3748/wjg.v25.i18.2188 PubMed
  21. [21] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
  22. [22] Mariana L Palma et al.. Appl Microbiol Biotechnol. 2019. Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate Gag-specific memory CD8+ T cells ex vivo. doi:10.1007/s00253-019-09842-8 PubMed
  23. [23] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
  24. [24] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
  25. [25] Jason C Sniffen et al.. PLoS One. 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. doi:10.1371/journal.pone.0209205 PubMed
  26. [26] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
  27. [27] Ivan D Florez et al.. PLoS One. 2018. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. doi:10.1371/journal.pone.0207701 PubMed
  28. [28] Jie Chen et al.. World J Pediatr. 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. doi:10.1007/s12519-018-0190-2 PubMed
  29. [29] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
  30. [30] Diego Currò et al.. Br J Pharmacol. 2017. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. doi:10.1111/bph.13632 PubMed
  31. [31] Jue-Rong Feng et al.. Eur J Clin Pharmacol. 2017. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. doi:10.1007/s00228-017-2291-6 PubMed
  32. [32] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
  33. [33] Iva Hojsak. Pediatr Gastroenterol Hepatol Nutr. 2017. Probiotics in Children: What Is the Evidence? doi:10.5223/pghn.2017.20.3.139 PubMed
  34. [34] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
  35. [35] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
  36. [36] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
  37. [37] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
  38. [38] Joshua Z Goldenberg et al.. Cochrane Database Syst Rev. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub4 PubMed
  39. [39] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
  40. [40] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
  41. [41] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
  42. [42] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
  43. [43] Ener Cagri Dinleyici et al.. Expert Opin Biol Ther. 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. doi:10.1517/14712598.2014.937419 PubMed
  44. [44] George Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  45. [45] G Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  46. [46] Angélica T Vieira et al.. Front Immunol. 2013. The role of probiotics and prebiotics in inducing gut immunity. doi:10.3389/fimmu.2013.00445 PubMed
  47. [47] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
  48. [48] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
  49. [49] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
  50. [50] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
  51. [51] Lynne V McFarland. World J Gastroenterol. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. doi:10.3748/wjg.v16.i18.2202 PubMed
  52. [52] Jean-François Bisson et al.. Dig Dis Sci. 2010. Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats : preventive effects of probiotics on TD. doi:10.1007/s10620-009-0822-4 PubMed
  53. [53] Kathleen Jones. J Spec Pediatr Nurs. 2010. Probiotics: preventing antibiotic-associated diarrhea. doi:10.1111/j.1744-6155.2010.00231.x PubMed
  54. [54] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
  55. [55] Yvan Vandenplas et al.. Eur J Pediatr. 2009. Saccharomyces boulardii in childhood. doi:10.1007/s00431-008-0879-7 PubMed
  56. [56] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
  57. [57] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
  58. [58] Benjamin Kligler et al.. Am Fam Physician. 2008. Probiotics. PubMed
  59. [59] Shira Idit Doron et al.. J Clin Gastroenterol. 2008. Probiotics for prevention of antibiotic-associated diarrhea. doi:10.1097/MCG.0b013e3181618ab7 PubMed
  60. [60] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
  61. [61] Silvia Salvatore et al.. Nutrition. 2007. Probiotics and zinc in acute infectious gastroenteritis in children: are they effective? doi:10.1016/j.nut.2007.03.008 PubMed
  62. [62] B C Johnston et al.. Cochrane Database Syst Rev. 2007. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub2 PubMed
  63. [63] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
  64. [64] Bradley C Johnston et al.. CMAJ. 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. doi:10.1503/cmaj.051603 PubMed
  65. [65] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
  66. [66] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
  67. [67] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
  68. [68] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
  69. [69] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
  70. [70] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.